Pemetrexed: Clinical Trials

3 trials for Pemetrexed, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 recruiting, 1 unknown. 3 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Active not recruiting 1, Recruiting 1, Unknown 1
Phase 11Active not recruiting 1

Follow Pemetrexed: new trials by email Literature Review of Pemetrexed trials Research Report on Pemetrexed

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis
QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Pemetrexed (Alimta) - Leptomeningeal Metastasis, Pemetrexed
Phase 1 / Phase 2Active not recruitingGuangzhou Medical University392025-03-172026-10-13
Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
Befotertinib combined Bevacizumab, Befotertinib combined platinum-based double chemotherapy - EGFR, Non-Small Cell Lung Cancer
Phase 2RecruitingPeng Zhang602024-11-072025-01-06
Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer
anlotinib plus chemotherapy, chemotherapy - Lung Neoplasms, Docetaxel
Phase 2UnknownThe First People's Hospital of Lianyungang602018-08-012018-07-18

Narrower conditions

Carcinoma, Non-Small-Cell Lung (1)  ·  Lung Neoplasms (1)  ·  Meningeal Carcinomatosis (1)

Broader conditions

Neoplasms (3)  ·  Neoplasms by Site (3)  ·  Lung Diseases (2)  ·  Respiratory Tract Diseases (2)  ·  Respiratory Tract Neoplasms (2)  ·  Thoracic Neoplasms (2)  ·  Bronchial Neoplasms (1)  ·  Carcinoma, Bronchogenic (1)  ·  Central Nervous System Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Meningeal Neoplasms (1)  ·  Nervous System Diseases (1)  ·  Nervous System Neoplasms (1)

Interventions

Drug Therapy (1)  ·  Pemetrexed (1)  ·  anlotinib (1)

Sponsors

Guangzhou Medical University (1)  ·  Peng Zhang (1)  ·  The First People's Hospital of Lianyungang (1)

Countries

China (3)

Top investigators

Zhenyu Pan, PhD,MD (1)